First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today ...

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...

Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

REDWOOD CITY, Calif. - Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company with a market capitalization of $3.08 billion, announced today the U.S. commercial availability of ...

(RTTNews) - Soleno Therapeutics, Inc. (SLNO), Monday said VYKAT XR which was approved by the Food and Drug Administration (FDA) on March 26 to treat hyperphagia in patients four years of age and ...